- Home
- DuoADC™: Precision Engagement, Amplified Efficacy
- Dual-Target Dynamic Screening Service
The dual-target dynamic screening service enables real-time, parallel pharmacological evaluation of two therapeutic targets through integrated biosensor monitoring and AI-driven data analytics. Alfa Cytology delivers end-to-end dual-target dynamic screening services, providing customized solutions for accelerated drug discovery with validated BBB-penetrating compound libraries.
Dual-target dynamic screening is a systematic approach to identify pairs of molecular targets suitable for dual-targeting ADC design. It combines target expression profiling, spatial co-localization analysis, and functional assessment to evaluate the relevance and compatibility of target combinations. The method enables rational selection based on co-expression, internalization potential, and tumor-specificity, supporting the development of ADCs with improved selectivity and reduced off-target effects.
Fig 1. The workflow of dual-target screening. (ZHANG L C, et al., 2022)
Increased Target Specificity
Dual-antigen recognition narrows binding to cells that co-express both markers, filtering out healthy tissues that display either antigen alone. This layered selectivity supports higher on-target engagement while lowering the likelihood of off-target interactions.
Improved Payload Delivery Efficiency
Simultaneous engagement of two receptors can accelerate receptor clustering and endocytosis, driving more ADC molecules into the endo-lysosomal pathway. The resulting boost in intracellular trafficking facilitates efficient payload release and heightened cytotoxic potency in preclinical systems.
Mitigation of Target Redundancy or Escape
Pairing mechanistically complementary antigens reduces dependence on a single pathway, limiting the impact of antigen down regulation or compensatory signaling. This redundancy guard enhances durability of response and curbs resistance emergence in heterogeneous tumor models.
Alfa Cytology possesses advanced assay platforms and bioinformatics capabilities to systematically evaluate dual-target combinations. Its integrated workflows support high-throughput screening, spatial profiling, and functional validation tailored to complex target biology.
Target Expression Profiling
Comprehensive analysis of target gene and protein expression across tumor models using transcriptomics, proteomics, and public databases to identify candidate target pairs.
Spatial Co-localization Assessment
Evaluation of the spatial distribution and co-expression of targets within tissues or cell populations using multiplex immunofluorescence or spatial transcriptomics.
Selectivity and Specificity Evaluation
Comparative analysis of target expression in tumor versus normal tissue models to prioritize combinations with higher selectivity and lower off-target risk.
Feasibility Testing with Dual-Binding Constructs
Optional production and evaluation of bispecific or dual-binding formats to assess binding efficiency, internalization, and cytotoxic potential in vitro.
Target Identification
Mining public and proprietary omics datasets to shortlist antigen pairs that are co-present on the intended cell type yet minimally expressed in essential healthy tissues.
Co-expression Confirmation
Verifying simultaneous surface display of each candidate pair across cell lines and primary samples through flow cytometry or immunostaining, ensuring practical accessibility for bispecific binding.
Functional Screening & Prioritization
Evaluating cell-based assays to measure additive or synergistic effects when both antigens are engaged, then ranking pairs by potency, selectivity, and manufacturability considerations.
Powered by state-of-the-art instrumentation and a highly skilled multidisciplinary team, Alfa Cytology rapidly identifies, prioritizes, and validates dual-target combinations, using integrated screening and data-analysis workflows to advance the most selective, biologically relevant pairs with exceptional efficiency. For further details or customized collaboration, please feel free to contact us.
Reference
For research use only, not for clinical use.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.